<DOC>
	<DOCNO>NCT02577094</DOCNO>
	<brief_summary>Determination maximum tolerate dose ( MTD ) fractionate RIT epratuzumab radiolabeled yttrium-90 ( 90Y-epratuzumab ) preceding reduce condition regimen FB2A2 allogeneic stem cell transplantation .</brief_summary>
	<brief_title>Testing Reduced Conditioning Regimen FB2A2 Preceded Fractionated Radio-immunotherapy ( RIT ) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>- Physical examination ( screen follow-up ) - Complete blood count ( screen follow-up ) - Dosage FLT3-ligand plasma ( screen follow-up ) - Blood ionogramme , creatinine hepatic work-up ( screen follow-up ) - Left ventricular ejection fraction pre-implant assessment - Immunization test ( screen follow-up ) - Bone marrow aspiration or/and blood CD 22 immunophenotype minimal residual disease evaluation ( screen follow-up ) - All exams initially abnormal necessary response evaluation All exams need case relapse suspicion . - Pharmacokinetic 90Y-hLL2</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Age ≥ 18 Acute lymphoblastic Leukemia ( ALL ) CD22 + Btype RC1 high risk BCell Acute Lymphoblastic Leukemia ( ALL ) CD22+ beyond RC1 . Expression CD22 ≥ 30 % tumor population evaluate flow cytometry immunohistochemistry diagnosis stage relapse stage . HLAidentical donor intra family , without major HLA mismatch ( 9 / 10th accept ) without contraindication stem cell mobilization ECOG ( Eastern Cooperative Oncology Group ) ≤ 2 Having receive previously Epratuzumab Eligible allograft reduce condition regimen With sign informed consent Patient age child bear adequate contraception Patient affiliate beneficiary National Health Service Tcell ALL Known hypersensibility 90YDOTAhLL2 Immunization hLL2 patient already receive one several injection antibody Patient eligible myeloablative conditioning regimen Other prior malignancy must least 2year diseasefree interval exception successfully treat carcinoma skin cancer carcinoma situ cervix . Patient progressive psychiatric condition . HIV positive , hepatitis Bantigen positive , hepatitis C positive patient need treatment Pregnant breastfeed woman Women childbearing potential without effective contraception Serious concomitant uncontrolled infection Usual contraindication allogeneic transplant : Adult patient protect French law</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CD22 positive- lymphoblastic leukemia-RIT-Yttrium</keyword>
</DOC>